Boston Scientific Announces Results For First Quarter Ended March 31, 2009

NATICK, Mass., April 20 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX) today announced financial results for the first
quarter ended March 31, 2009, as well as guidance for net sales and earnings
per share (EPS) for the second quarter and full year of 2009.

First Quarter Highlights (Sales growth rates are constant currency):

-- Achieved sales of $2.010 billion and adjusted EPS of $0.19, both in
line
with guidance (GAAP loss per share of $0.01)
-- Increased worldwide sales of cardiac rhythm management (CRM) products
nine percent, including a 13 percent increase in implantable
cardioverter defibrillator (ICD) sales
-- Increased U.S. CRM sales 11 percent, including a 14 percent increase
in
ICD sales, the fourth consecutive quarter of double-digit U.S. CRM
growth
-- Expanded worldwide drug-eluting stent (DES) leadership to 44 percent
market share; increased U.S. market share to 50 percent: 27 percent
TAXUS(R), 23 percent PROMUS(R)
-- Successfully launched the next-generation TAXUS(R) Liberte(R)
Paclitaxel-Eluting Coronary Stent System in Japan, achieved 54 percent
market share
-- Increased worldwide Endoscopy sales six percent, Urology/Gynecology
seven percent and Neuromodulation nine percent

-- Received rating outlook upgrades from Moody's and Standard and
Poor's

"We're off to a good start on the year with four percent sales growth,
excluding divestitures, on a constant currency basis and adjusted EPS at the
high end of our guidance range," said Jim Tobin, President and Chief Executive
Officer of Boston Scientific. "Our CRM and DES results were particularly
impressive, with double-digit U.S. growth in both businesses. We also saw
continued solid performances by our Endoscopy, Urology/Gynecology and
Neuromodulation businesses. We further reduced risk by settling additional
litigation, pre-paying debt, amending our credit facility, and maintaining
financial discipline and strong cash flow."

Net sales for the first quarter of 2009 were $2.010 billion, which included
sales from divested businesses of $4 million, as compared to net sales of
$2.046 billion for the first quarter of 2008, which included sales from
divested businesses of $32 million. Excluding the impact of foreign currency
and sales from divested businesses, net sales increased four percent over the
prior year.

Worldwide sales of the Company's CRM products for the first quarter were
as follows:

(in millions) U.S. International Worldwide
Q1 2009 Q1 2008 Q1 2009 Q1 2008 Q1 2009 Q1 2008
ICD systems $312 $274 $132 $137 $444 $411
Pacemaker
systems 84 82 61 72 145 154

Total CRM
products $396 $356 $193 $209 $589 $565

Worldwide sales of the Company's coronary stent systems for the first
quarter were as follows:

(in millions) U.S. International Worldwide
Q1 2009 Q1 2008 Q1 2009 Q1 2008 Q1 2009 Q1 2008
Drug-eluting $246 $218 $199 $210 $445 $428
Bare-metal 16 26 28 36 44 62

Total coronary
stent systems $262 $244 $227 $246 $489 $490

Reported net loss for the first quarter of 2009 was $13 million, or $0.01 per
share. Reported results included acquisition-, divestiture-, litigation-, and
restructuring-related net charges; discrete tax items and amortization expense
(after-tax) of $302 million, or $0.20 per share, which consisted primarily of:

-- $240 million ($287 million pre-tax) of litigation-related charges
associated with various patent litigation matters;
-- $26 million ($37 million pre-tax) of restructuring and
restructuring-related charges associated with the Company's plant
network optimization plan and expense and head count reduction
initiatives;
-- a $63 million credit, on both a pre-tax and after-tax basis, of
discrete
tax items related to certain tax positions associated with prior
period
divestiture-related charges; and

-- $101 million ($128 million pre-tax) of amortization expense.

Adjusted net income for the first quarter of 2009, excluding these charges,
was $289 million, or $0.19 per share. Included in the reported and adjusted
net income was $11 million, or $0.01 per share, of favorable discrete income
tax items.

Reported net income for the first quarter of 2008 was $322 million, or $0.21
per share. Reported results included acquisition-, divestiture-, litigation-,
and restructuring-related charges; and amortization expense (after-tax) of $35
million, or $0.03 per share. Adjusted net income for the first quarter of
2008, excluding these charges, was $357 million, or $0.24 per share. Included
in the reported and adjusted net income was $43 million, or $0.03 per share,
of favorable discrete income tax items and $8 million, or $0.01 per share,
associated with divested businesses.

Guidance for Second Quarter and Full Year 2009

The Company estimates net sales for the second quarter of 2009 of between
$1.960 billion and $2.080 billion, which includes an estimated $100 million
negative impact from foreign currency exchange as compared to the second
quarter of 2008. Excluding the impact of foreign currency and sales from
divested businesses, the Company estimates net sales growth rates of three
percent to nine percent during the second quarter of 2009. Adjusted earnings,
excluding acquisition-, divestiture-, litigation- and restructuring-related
charges; and amortization expense, are estimated to range between $0.16 and
$0.21 per share. The Company estimates net income on a GAAP basis of between
$0.07 and $0.13 per share.

The Company reaffirms its net sales estimate for the full year of 2009 of
between $8.0 billion and $8.5 billion. The Company also continues to expect
adjusted earnings, excluding acquisition-, divestiture-, litigation- and
restructuring-related charges; discrete tax items, and amortization expense,
for the full year of between $0.80 and $0.90 per share. The Company now
expects net income on a GAAP basis of between $0.46 and $0.57 per share, as a
result of first quarter litigation-related charges and discrete tax items.

"This guidance reflects our optimism about the growth potential of all our
businesses, which are benefiting from our renewed focus on product development
and increasing sales profitably," said Tobin. "Our momentum is building, and
we are particularly enthusiastic about our prospects for the second half of
the year, which we believe will contribute to a very strong 2009."

Boston Scientific officials will be discussing these results with analysts on
a conference call at 8:00 a.m. (ET) Tuesday, April 21, 2009. The Company will
webcast the call to all interested parties through its website:
www.bostonscientific.com. Please see the website for details on how to access
the webcast. The webcast will be available for one year on the Boston
Scientific website.

Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices whose products are used in a broad range of interventional
medical specialties. For more information, please visit:
www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements may be identified by words like "anticipate," "expect," "project,"
"believe," "plan," "estimate," "intend" and similar words. These
forward-looking statements are based on our beliefs, assumptions and estimates
using information available to us at the time and are not intended to be
guarantees of future events or performance. These forward-looking statements
include, among other things, statements regarding our financial performance,
our growth strategy, new product approvals, our market position, acquisitions
and divestitures, restructuring activities and litigation matters. If our
underlying assumptions turn out to be incorrect, or if certain risks or
uncertainties materialize, actual results could vary materially from the
expectations and projections expressed or implied by our forward-looking
statements. These factors, in some cases, have affected and in the future
(together with other factors) could affect our ability to implement our
business strategy and may cause actual results to differ materially from those
contemplated by the statements expressed in this press release. As a result,
readers are cautioned not to place undue reliance on any of our
forward-looking statements.

Factors that may cause such differences include, among other things: future
economic, competitive, reimbursement and regulatory conditions; new product
introductions; demographic trends; intellectual property; litigation;
financial market conditions; and future business decisions made by us and our
competitors. All of these factors are difficult or impossible to predict
accurately and many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties that may
affect our future operations, see Part I, Item IA- Risk Factors in our most
recent Annual Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A - Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file thereafter. We
disclaim any intention or obligation to publicly update or revise any
forward-looking statements to reflect any change in our expectations or in
events, conditions, or circumstances on which those expectations may be based,
or that may affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary statement is
applicable to all forward-looking statements contained in this document.

Use of non-GAAP Financial Information

A reconciliation of the Company's non-GAAP financial measures to the
corresponding GAAP measures, and an explanation of the Company's use of these
non-GAAP measures, is included in the exhibits attached to this press release.

CONTACT:

Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations
Boston Scientific Corporation

Larry Neumann
508-650-8696 (office)
Investor Relations
Boston Scientific Corporation

BOSTON SCIENTIFIC CORPORATION
CONDENSED CONSOLIDATED GAAP RESULTS OF OPERATIONS
(Unaudited)

Three Months Ended
March 31,
In millions, except per share data 2009 2008
Net sales $2,010 $2,046
Cost of products sold 607 580
Gross profit 1,403 1,466

Operating expenses:
Selling, general and administrative expenses 651 661
Research and development expenses 257 244
Royalty expense 46 46
Amortization expense 128 143
Purchased research and development 13
Gain on divestitures (250)
Restructuring charges 23 29
Litigation-related charges 287
1,392 886
Operating income 11 580

Other income (expense):
Interest expense (102) (131)
Other, net (6) 13

(Loss) income before income taxes (97) 462
Income tax (benefit) expense (84) 140
Net (loss) income $(13) $322

Net (loss) income per common share - basic $(0.01) $0.22
Net (loss) income per common share - assuming
dilution $(0.01) $0.21

Weighted average shares outstanding - basic 1,504.8 1,494.1
Weighted average shares outstanding - assuming
dilution 1,504.8 1,500.1

BOSTON SCIENTIFIC CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS

March 31, December 31,
In millions 2009 2008
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents $897 $1,641
Trade accounts receivable, net 1,369 1,402
Inventories 852 853
Deferred income taxes 941 911
Assets held for sale 13 13
Prepaid expenses and other current assets 579 632
Total current assets 4,651 5,452

Property, plant and equipment, net 1,708 1,728
Investments 109 113
Other assets 175 181
Intangible assets, net 19,539 19,665
$26,182 $27,139

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current debt obligations $5 $2
Accounts payable 254 239
Accrued expenses 2,014 2,612
Income taxes payable 8 161
Other current liabilities 150 219
Total current liabilities 2,431 3,233

Long-term debt 6,242 6,743
Deferred income taxes 2,322 2,262
Other long-term liabilities 1,911 1,727

Stockholders' equity 13,276 13,174
$26,182 $27,139

BOSTON SCIENTIFIC CORPORATION
NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS
(Unaudited)

Three Months Ended March 31,
2009 2008
In millions, except Net Impact per Impact per
per share data (loss) diluted Net diluted
income share income share
GAAP results $(13) $(0.01) $322 $0.21
Non-GAAP adjustments:
Acquisition-related charges 8 0.01
Divestiture-related gains (2) (0.00) (114) (0.08)
Restructuring-related charges 26 0.02* 32 0.02
Litigation-related charges 240 0.15*
Discrete tax items (63) (0.04)*
Amortization expense 101 0.07* 109 0.08
Adjusted results $289 $0.19 $357 $0.24

* Assumes dilution of 3.9 million shares for all or a portion of these
non-GAAP adjustments.

An explanation of the Company's use of these non-GAAP measures is
provided at the end of this document.

BOSTON SCIENTIFIC CORPORATION
NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS
(CONT.)
(Unaudited)

Three Months Ended
March 31,
2009 2008
Acquisition-related charges:
Purchased research and development $13
Less: Income tax benefit (a) 5
Acquisition-related charges, net of tax $8

Divestiture-related gains:
Gain on sale of investments (b) $(3)
Gain on divestitures $(250)
Less: Income tax expense (a) 1 136
Divestiture-related gains, net of tax $(2) $(114)

Restructuring-related charges:
Restructuring charges $23 $29
Restructuring-related charges (c) 14 15
37 44
Less: Income tax benefit (a) 11 12
Restructuring-related charges, net of tax $26 $32

Litigation-related charges:
Litigation-related charges $287
Less: Income tax benefit (a) 47
Litigation-related charges, net of tax $240

Discrete tax items:
Income tax benefit (a) $(63)

Amortization expense:
Amortization expense $128 $143
Less: Income tax benefit (a) 27 34
Amortization expense, net of tax $101 $109

(a) Amounts are tax effected at the Company's effective tax rate,
unless the amount is a significant unusual or infrequently
occurring item in accordance with FASB Interpretation No. 18,
"Accounting for Income Taxes in Interim Periods."
(b) Recorded in other, net.
(c) In 2009, recorded $10 million to cost of products sold; $3 million
to selling, general and administrative expenses; and $1 million to
research development expenses. In 2008, recorded $4 million to cost
of products sold; $9 million to selling, general and administrative
expenses; and $2 million to research and development expenses.

An explanation of the Company's use of these non-GAAP measures is
provided at the end of this document.

BOSTON SCIENTIFIC CORPORATION
WORLDWIDE SALES
(Unaudited)

Change
As
Three Months Ended Reported Constant
March 31, Currency Currency
In millions 2009 2008 Basis Basis

United States $1,170 $1,117 5% 5%

EMEA 446 507 (12)% 3%
Japan 243 222 9% (2)%
Inter-Continental 147 168 (13)% 6%
International 836 897 (7)% 2%

Subtotal 2,006 2,014 -% 4%

Divested Businesses 4 32 N/A N/A

Worldwide $2,010 $2,046 (2)% 2%

Change
As
Three Months Ended Reported Constant
March 31, Currency Currency
In millions 2009 2008 Basis Basis

Interventional Cardiology $738 $756 (3)% 1%
Peripheral Interventions 158 177 (12)% (7)%
Cardiovascular 896 933 (4)% -%

Neurovascular 87 92 (5)% -%

Cardiac Rhythm Management 589 565 4% 9%
Electrophysiology 37 38 (3)% (1)%
Cardiac Rhythm Management 626 603 4% 8%

Endoscopy 232 229 1% 6%
Urology 104 100 5% 7%
Endosurgery 336 329 2% 7%

Neuromodulation 61 57 8% 9%

Subtotal 2,006 2,014 -% 4%

Divested Businesses 4 32 N/A N/A

Worldwide $2,010 $2,046 (2)% 2%

An explanation of the Company's use of these non-GAAP measures is
provided at the end of this document.

BOSTON SCIENTIFIC CORPORATION
NON-GAAP CONSTANT CURRENCY NET SALES RECONCILIATIONS
(Unaudited)

Q1 2009 Net Sales as compared to Q1 2008

Change Estimated
As Reported Constant Impact of
Currency Currency Foreign
In millions Basis Basis Currency

United States $53 $53 $-

EMEA (61) 16 (77)
Japan 21 (4) 25
Inter-Continental (21) 12 (33)
International (61) 24 (85)

Subtotal (8) 77 (85)

Divested Businesses (28) (28) -

Worldwide $(36) $49 $(85)

Q1 2009 Net Sales as compared to Q1 2008

Change Estimated
As Reported Constant Impact of
Currency Currency Foreign
In millions Basis Basis Currency

Interventional Cardiology $(18) $11 $(29)
Peripheral Interventions (19) (12) (7)
Cardiovascular (37) (1) (36)

Neurovascular (5) - (5)

Cardiac Rhythm Management 24 51 (27)
Electrophysiology (1) - (1)
Cardiac Rhythm Management 23 51 (28)

Endoscopy 3 15 (12)
Urology 4 7 (3)
Endosurgery 7 22 (15)

Neuromodulation 4 5 (1)

Subtotal (8) 77 (85)

Divested Businesses (28) (28) -

Worldwide $(36) $49 $(85)

An explanation of the Company's use of these non-GAAP measures is
provided at the end of this document.

BOSTON SCIENTIFIC CORPORATION
WORLDWIDE NET SALES GUIDANCE
(Unaudited)

Change
Three Months As
Ended Reported Constant
June 30, Currency Currency
In millions 2009 2008 Basis Basis

Estimated worldwide net
sales - high $2,080 $2,024 3%
Less: Net sales from divested
businesses 19
Adjusted estimated worldwide net
sales - high $2,080 $2,005 4% 9%

Estimated worldwide net
sales - low $1,960 $2,024 (3%)
Less: Net sales from divested
businesses 19
Adjusted estimated worldwide net
sales - low $1,960 $2,005 (2%) 3%

BOSTON SCIENTIFIC CORPORATION
NON-GAAP CONSTANT CURRENCY NET SALES RECONCILIATION
(Unaudited)

Q2 2009 Net Sales as compared to Q2 2008
Change
As Estimated
Reported Constant Impact of
Currency Currency Foreign
In millions Basis Basis Currency

Adjusted estimated worldwide
net sales - high $75 $175 $(100)
Adjusted estimated worldwide
net sales - low $(45) $55 $(100)

An explanation of the Company's use of these non-GAAP measures is
provided at the end of this document.

BOSTON SCIENTIFIC CORPORATION
ESTIMATED NON-GAAP NET INCOME PER COMMON SHARE RECONCILIATIONS
(Unaudited)

Q2 2009 Estimate Q2 2009 Estimate
(Low) (High)
GAAP results $0.07 $0.13

Estimated restructuring-related charges 0.02 0.01
Estimated amortization expense 0.07 0.07

Adjusted results $0.16 $0.21

2009 Estimate 2009 Estimate
(Low) (High)
GAAP results $ 0.46 $ 0.57

Estimated acquisition-related credits (0.12) (0.12)
Estimated restructuring-related charges 0.08 0.07
Estimated litigation-related charges 0.15 0.15
Estimated discrete tax items (0.04) (0.04)
Estimated amortization expense 0.27 0.27

Adjusted results $ 0.80 $ 0.90

An explanation of the Company's use of these non-GAAP measures is
provided at the end of this document.

Use of Non-GAAP Financial Measures

To supplement Boston Scientific's condensed consolidated financial statements
presented on a GAAP basis; the Company discloses certain non-GAAP measures
that exclude certain amounts, including non-GAAP net income, non-GAAP net
income per share, and regional and divisional revenue growth rates that
exclude the impact of foreign exchange. These non-GAAP measures are not in
accordance with, or an alternative for, generally accepted accounting
principles in the United States.

The GAAP measure most comparable to non-GAAP net income is GAAP net income and
the GAAP measure most comparable to non-GAAP net income per share is GAAP net
income per share. Reconciliations of each of these non-GAAP financial measures
to the corresponding GAAP measure are included in the accompanying schedules.

To calculate regional and divisional revenue growth rates that exclude the
impact of foreign exchange, the Company converts actual current-period net
sales from local currency to U.S. dollars using constant foreign exchange
rates. The GAAP measure most comparable to this non-GAAP measure is growth
rate percentages based on GAAP revenue. A reconciliation of this non-GAAP
financial measure to the corresponding GAAP measure is included in the
accompanying schedules.

Use and Economic Substance of Non-GAAP Financial Measures Used by Boston
Scientific
Management uses these supplemental non-GAAP measures to evaluate performance
period over period, to analyze the underlying trends in the Company's
business, to assess its performance relative to its competitors, and to
establish operational goals and forecasts that are used in allocating
resources. In addition, management uses these non-GAAP measures to further its
understanding of the performance of the Company's operating segments. The
adjustments excluded from the Company's non-GAAP measures are consistent with
those excluded from its reportable segments' measure of profit or loss. These
adjustments are excluded from the segment measures that are reported to the
Company's chief operating decision maker and are used to make operating
decisions and assess performance.

The following is an explanation of each of the adjustments that management
excluded as part of its non-GAAP measures for the three months ended March 31,
2009 and 2008 and for the forecasted three month period ending June 30, 2009,
as well as reasons for excluding each of these individual items:

-- Acquisition-related charges - These adjustments consist of purchased
research and development. Purchased research and development is a
highly
variable charge based on valuation assumptions. Management removes the
impact of purchased research and development from the Company's
operating results to facilitate an evaluation of the Company's
current operating performance and a comparison to the Company's
past operating performance.

-- Divestiture-related gains and losses - These amounts represent gains
and
losses, and related tax impacts, that the Company recognized related
to
the sale of non-strategic assets, including the sale of certain
businesses, development programs and non-strategic investments. The
sale
and transfer of these non-strategic assets were substantially
completed
during 2008. These gains and losses are not indicative of future
operating performance and are not used by management to assess
operating
performance. Accordingly, management excluded these amounts for
purposes
of calculating these non-GAAP measures to facilitate an evaluation of
the Company's current operating performance and a comparison to the
Company's past operating performance.

-- Restructuring-related charges - These adjustments primarily represent
severance, employee-related retention incentives, asset write-offs,
accelerated depreciation, costs to transfer production lines from one
facility to another, and other costs associated with the Company's
restructuring initiatives. These expenses are not indicative of the
Company's on-going operating performance and are excluded by
management in assessing the Company's operating performance, as
well as from the Company's operating segments' measures of
profit and loss used for making operating decisions and assessing
performance. Accordingly, management excluded these charges for
purposes
of calculating these non-GAAP measures to facilitate an evaluation of
the Company's current operating performance and a comparison to the
Company's past operating performance.

-- Litigation-related charges -These charges are attributable to certain
patent litigation matters. These amounts represent significant charges
during the first quarter of 2009 and do not reflect expected on-going
operating expenses. Accordingly, management excluded these charges for
purposes of calculating these non-GAAP measures to facilitate an
evaluation of the Company's current operating performance and for
comparison to the Company's past operating performance.

-- Discrete tax items - These items represent current period adjustments
of
certain tax positions, which were initially recorded in prior periods
associated with the Company's acquisition-, divestiture-,
litigation- and restructuring related charges. These adjustments do
not
reflect expected on-going operating results. Accordingly, management
excluded these amounts for purposes of calculating these non-GAAP
measures to facilitate an evaluation of the Company's current
operating performance and for comparison to the Company's past
operating performance.

-- Amortization expense - Amortization expense is a non-cash charge and
does not impact the Company's liquidity or compliance with the
covenants included in its debt agreements. Management removes the
impact
of amortization from the Company's operating performance to assist
in assessing the Company's cash generated from operations.
Management believes this is a critical metric for the Company in
measuring the Company's ability to generate cash and pay down debt.
Therefore, amortization expense is excluded from management's
assessment of operating performance and is also excluded from the
measures management uses to set employee compensation. Accordingly,
management believes this may be useful information to users of its
financial statements and therefore has excluded amortization expense
for
purposes of calculating these non-GAAP measures to facilitate an
evaluation of the Company's current operating performance,
particularly in terms of liquidity.

-- Foreign exchange on net sales - The impact of foreign exchange is
highly
variable and difficult to predict. Accordingly, management excludes
the
impact of foreign exchange for purposes of reviewing regional and
divisional revenue growth rates to facilitate an evaluation of the
Company's current operating performance and comparison to the
Company's past operating performance.

Material Limitations Associated with the Use of Non-GAAP Financial Measures
Non-GAAP net income, non-GAAP net income per diluted share, and regional and
divisional revenue growth rates that exclude the impact of foreign exchange
may have limitations as analytical tools, and these non-GAAP measures should
not be considered in isolation from or as a replacement for GAAP financial
measures. Some of the limitations associated with the use of these non-GAAP
financial measures are:

-- Items such as purchased research and development and
divestiture-related
gains and losses reflect economic costs to the Company and are not
reflected in non-GAAP net income and non-GAAP net income per diluted
share.

-- Restructuring-related expenses that are excluded from non-GAAP net
income and non-GAAP net income per diluted share can have a material
impact on cash flows and GAAP net income and net income per diluted
share.

-- Amortization expense, though not directly affecting Boston
Scientific's cash flow position, represents a reduction in value of
intangible assets. The expense associated with this reduction in value
is not included in Boston Scientific's non-GAAP net income or
non-GAAP net income per diluted share and therefore these measures do
not reflect the full economic effect of the reduction in value of
those
intangible assets.

-- Revenue growth rates stated on a constant currency basis, by their
nature, exclude the impact of foreign exchange, which may have a
material impact on GAAP net sales.

-- Other companies may calculate non-GAAP net income, non-GAAP net income
per diluted share, or regional and divisional revenue growth rates
that
exclude the impact of foreign exchange differently than Boston
Scientific does, limiting the usefulness of those measures for
comparative purposes.

Compensation for Limitations Associated with Use of Non-GAAP Financial
Measures
Boston Scientific compensates for the limitations on its non-GAAP financial
measures by relying upon its GAAP results to gain a complete picture of the
Company's performance. The non-GAAP numbers focus instead upon the core
business of the Company, which is only a subset, albeit a critical one, of the
Company's performance.

The Company provides detailed reconciliations of each non-GAAP financial
measure to its most directly comparable GAAP measure in the accompanying
schedules, and Boston Scientific encourages investors to review these
reconciliations.

Usefulness of Non-GAAP Financial Measures to Investors
The Company believes that presenting non-GAAP net income, non-GAAP net income
per share, and regional and divisional revenue growth rates that exclude the
impact of foreign exchange in addition to the related GAAP measures provides
investors greater transparency to the information used by Boston Scientific
management for its financial and operational decision-making and allows
investors to see Boston Scientific's results "through the eyes" of management.
The Company further believes that providing this information better enables
Boston Scientific's investors to understand the Company's operating
performance and to evaluate the methodology used by management to evaluate and
measure such performance.

SOURCE Boston Scientific Corporation

Media Relations, Paul Donovan, +1-508-650-8541, mobile, +1-508-667-5165, or
Investor Relations, Larry Neumann, +1-508-650-8696, both of Boston Scientific
Corporation